S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
NASDAQ:LMDX

LumiraDx Stock Forecast, Price & News

$9.48
-0.28 (-2.87%)
(As of 12/6/2021 10:50 AM ET)
Add
Compare
Today's Range
$9.48
$9.48
50-Day Range
$7.29
$10.49
52-Week Range
$7.15
$11.09
Volume
100 shs
Average Volume
414,587 shs
Market Capitalization
$34.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive LMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.


LumiraDx logo

About LumiraDx

LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx Limited, formerly known as CA Healthcare Acquisition Corp., is based in BOSTON.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMDX
Web
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$50.78 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$34.61 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/09/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

814th out of 1,390 stocks

Pharmaceutical Preparations Industry

389th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












LumiraDx (NASDAQ:LMDX) Frequently Asked Questions

Is LumiraDx a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LumiraDx stock.
View analyst ratings for LumiraDx
or view top-rated stocks.

When is LumiraDx's next earnings date?

LumiraDx is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for LumiraDx
.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $109.08 million for the quarter, compared to analyst estimates of $100.84 million.
View LumiraDx's earnings history
.

What price target have analysts set for LMDX?

3 Wall Street analysts have issued 12-month price objectives for LumiraDx's stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate LumiraDx's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price.
View analysts' price targets for LumiraDx
or view top-rated stocks among Wall Street analysts.

What is LumiraDx's stock symbol?

LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."

Who are LumiraDx's major shareholders?

LumiraDx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bill & Melinda Gates Foundation (152.67%), Senvest Management LLC (25.07%), Moore Capital Management LP (3.41%), Omni Partners US LLC (2.63%), Ionic Capital Management LLC (2.59%) and Caas Capital Management LP (1.40%).

Which institutional investors are buying LumiraDx stock?

LMDX stock was purchased by a variety of institutional investors in the last quarter, including Bill & Melinda Gates Foundation, Senvest Management LLC, Moore Capital Management LP, Omni Partners US LLC, Ionic Capital Management LLC, Caas Capital Management LP, Granby Capital Management LLC, and Citadel Advisors LLC.

How do I buy shares of LumiraDx?

Shares of LMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LumiraDx's stock price today?

One share of LMDX stock can currently be purchased for approximately $9.48.

How much money does LumiraDx make?

LumiraDx has a market capitalization of $34.61 million.

How many employees does LumiraDx have?

LumiraDx employs 2 workers across the globe.

Where are LumiraDx's headquarters?

LumiraDx is headquartered at 99 SUMMER STREET SUITE 200, BOSTON MA, 02110.

How can I contact LumiraDx?

LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The company can be reached via phone at 617-314-3901.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.